Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed KMT2Ar or NUP98r AML (REVEAL-ND KMT2A)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with acute myeloid leukemia (AML) with certain genetic mutations compared to chemotherapy alone. The study will also assess the safety of adding revumenib to chemotherapy
Epistemonikos ID: 3f05f99557debca34d3e5f2eab3b8cdce295a64e
First added on: Oct 09, 2025